Clinical trial
A Randomized, Double-blind Placebo-controlled Study of Recombinant Human B Lymphocyte Stimulating Factor Receptor-Fc Fusion Protein for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
NCT05998759 is registered in ClinicalTrials.gov with Beijing Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind Placebo-controlled Study of Recombinant Human B Lymphocyte Stimulating Factor Receptor-Fc Fusion Protein for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
- Lead sponsor
- Beijing Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 2, 2023
- Completion date
- December 31, 2025
- Enrollment
- 296 (estimated)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.